- AHA News: Family’s Hereditary Heart Condition Discovered After Her Father and Two Sisters Died Young
- You Can Take Too Much Vitamin D — One Man Found Out the Hard Way
- About 1 in 7 U.S. Kindergarten Kids Now Obese
- FDA Temporarily Suspends Ban on Juul E-Cigarettes
- Teens Have Triple the Odds of Misusing Marijuana Compared to Adults
- Age Big Factor in COVID Vaccine Views
- Do Preteens Think About Booze, Pot? Survey Says Yes
- Health Highlights: July 6, 2022
- A-Fib After Any Surgery Raises Odds for Heart Failure
- Many Gen Z Americans Have Sun Safety All Wrong
Perjeta Approved for Early Stage Breast Cancer

MONDAY, Sept. 30The anti-cancer drug Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat early-stage breast cancer before surgery, the agency said Monday.
In 2012, the drug was approved to treat advanced or spreading (metastatic) HER-2 positive breast cancer, which is triggered by increased amounts of a protein that fuels the growth of cancer cells, the FDA said in a news release.
The drug’s new use is meant for people with HER-2 positive early-stage breast cancer who are at increased risk of the cancer returning, spreading or of dying from the disease, the agency said. The drug is to be used with in combination with chemotherapy before surgery.
Perjeta’s safety and effectiveness were evaluated for the new use in a clinical study involving 417 people, the FDA said. A “confirmatory” study involving more than 4,800 people is ongoing, with results expected in 2016.
Perjeta is marketed by San Francisco-based Genentech, a member of the Roche Group.
More information
To learn more about this approval, visit the FDA.
Source: HealthDay